ifosfamide and aprepitant

ifosfamide has been researched along with aprepitant in 14 studies

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (35.71)29.6817
2010's6 (42.86)24.3611
2020's3 (21.43)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Durand, JP; Goldwasser, F; Gourmel, B; Mir, O1
Hatfield Seung, A; Howell, JE; Nesbit, SA; Szabatura, AH1
Jarkowski, A1
Romanick, M; Shiu, JR; Stobart, K1
Yuen, C1
Behlendorf, T; Jahn, F; Jahn, P; Jordan, K; Kegel, T; Ruessel, J; Schmoll, HJ; Stein, A1
Bärlund, M; Sunela, K1
Akashi, K; Arita, S; Ariyama, H; Baba, E; Harimaya, K; Inadomi, K; Kumagai, H; Kusaba, H; Matsunobu, T; Takayoshi, K1
Mohammadpour, AH; Rahimi, H; Sadeghi, M; Samadi, S; Vazirian, F1
Allal, B; Chaltiel, L; Chatelut, E; Chevreau, C; Filleron, T; Firmin, N; Lambert, M; Mseddi, M; Toulmonde, M; Valentin, T; Yakoubi, M1
Kawai, A; Kobayashi, E; Sano, T; Setsu, N1

Reviews

3 review(s) available for ifosfamide and aprepitant

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
[Treatment and prevention of iphosphamide-induced encephalopathy].
    Duodecim; laaketieteellinen aikakauskirja, 2016, Volume: 132, Issue:4

    Topics: Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Drug Interactions; Enzyme Inhibitors; Humans; Ifosfamide; Methylene Blue; Morpholines; Neurotoxicity Syndromes

2016
Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review.
    Cancer chemotherapy and pharmacology, 2022, Volume: 90, Issue:1

    Topics: Aprepitant; Humans; Ifosfamide; Morpholines; Neurotoxicity Syndromes; Randomized Controlled Trials as Topic; Retrospective Studies

2022

Trials

1 trial(s) available for ifosfamide and aprepitant

ArticleYear
The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.
    Bone marrow transplantation, 2011, Volume: 46, Issue:6

    Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Granisetron; Humans; Ifosfamide; Male; Melphalan; Middle Aged; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Paclitaxel; Treatment Outcome; Vomiting; Young Adult

2011

Other Studies

10 other study(ies) available for ifosfamide and aprepitant

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:4

    Topics: Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Brain Diseases; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Humans; Ifosfamide; Middle Aged; Morpholines

2007
Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2008, Volume: 14, Issue:3

    Topics: Antidotes; Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Delirium; Female; Humans; Ifosfamide; Kidney Function Tests; Liver Function Tests; Male; Methylene Blue; Middle Aged; Morpholines; Neuropsychological Tests; Neurotoxicity Syndromes; Retrospective Studies; Sarcoma

2008
Possible contribution of aprepitant to ifosfamide-induced neurotoxicity.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Dec-01, Volume: 65, Issue:23

    Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Dexamethasone; Drug Therapy, Combination; Etoposide; Humans; Ifosfamide; Male; Morpholines; Nausea; Nerve Sheath Neoplasms; Neurotoxicity Syndromes

2008
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in adolescents.
    Pediatric blood & cancer, 2009, Dec-15, Volume: 53, Issue:7

    Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Cisplatin; Cyclophosphamide; Double-Blind Method; Drug Interactions; Etoposide; Fever; Humans; Ifosfamide; Incidence; Morpholines; Nausea; Neutropenia; Randomized Controlled Trials as Topic; Sample Size; Vomiting

2009
Aprepitant-associated ifosfamide neurotoxicity.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2010, Volume: 16, Issue:2

    Topics: Adult; Antidepressive Agents; Antineoplastic Agents, Alkylating; Aprepitant; Case-Control Studies; Female; Humans; Ifosfamide; Male; Middle Aged; Morpholines; Neurotoxicity Syndromes; Retrospective Studies; Sarcoma

2010
Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy.
    Medicine, 2016, Volume: 95, Issue:49

    Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Doxorubicin; Female; Humans; Ifosfamide; Male; Middle Aged; Morpholines; Nausea; Retrospective Studies; Sarcoma; Treatment Outcome; Young Adult

2016
Population pharmacokinetic analysis reveals no impact of aprepitant on the pharmacokinetics of ifosfamide, 2-dechloroifosfamide, and 3-dechloroifosfamide.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2023, Jun-01, Volume: 185

    Topics: Antiemetics; Aprepitant; Humans; Ifosfamide; Retrospective Studies; Sarcoma

2023
[Errata: A Case of Encephalopathy Caused by Drug Interaction between Ifosfamide and Aprepitant].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2023, Volume: 143, Issue:7

    Topics: Antiemetics; Aprepitant; Brain Diseases; Drug Interactions; Humans; Ifosfamide

2023